Göbel Carl H, Heinze Axel, Karstedt Sarah, Morscheck Mascha, Tashiro Lilian, Cirkel Anna, Hamid Qutayba, Halwani Rabih, Temsah Mohamad-Hani, Ziemann Malte, Görg Siegfried, Münte Thomas, Göbel Hartmut
Department of Neurology, University Hospital Schleswig-Holstein, Lübeck, Germany.
Kiel Migraine and Headache Centre, Kiel, Germany.
Brain Commun. 2021 Jul 23;3(3):fcab169. doi: 10.1093/braincomms/fcab169. eCollection 2021.
The novel coronavirus SARS-CoV-2 causes the infectious disease COVID-19. Newly developed mRNA vaccines can prevent the spread of the virus. Headache is the most common neurological symptom in over 50% of those vaccinated. Detailed information about the clinical characteristics of this form of headache has not yet been described. The aim of the study is to examine in detail the clinical characteristics of headaches occurring after vaccination against COVID-19 with the BNT162b2 mRNA COVID-19 vaccine for the first time. In a multicentre observational cohort study, data on the clinical features and corresponding variables were recorded using a standardized online questionnaire. The questionnaire was circulated to 12 000 residential care homes of the elderly as well as tertiary university hospitals in Germany and the United Arab Emirates. The primary outcomes of this study are the clinical features of headache after vaccination. Comorbidities, treatment with medication and sociodemographic variables are also analysed. A total of 2349 participants reported headaches after vaccination with the BNT162b2 mRNA COVID-19 vaccine. Headaches occur an average of 18.0 ± 27.0 h after vaccination and last an average duration of 14.2 ± 21.3 h. Only 9.7% of those affected also report headaches resulting from previous vaccinations. In 66.6% of the participants, headache occurs as a single episode. A bilateral location is indicated by 73.1% of the participants. This is most often found on the forehead (38.0%) and temples (32.1%). A pressing pain character is indicated by 49.2% and 40.7% report a dull pain character. The pain intensity is most often moderate (46.2%), severe (32.1%) or very severe (8.2%). The most common accompanying symptoms are fatigue (38.8%), exhaustion (25.7%) and muscle pain (23.4%). Headaches after COVID-19 vaccination show an extensive complex of symptoms. The constellation of accompanying symptoms together with the temporal and spatial headache characteristics delimit a distinctive headache phenotype.
新型冠状病毒SARS-CoV-2引发了COVID-19传染病。新研发的mRNA疫苗可预防该病毒传播。超过50%的接种者中，头痛是最常见的神经症状。关于这种头痛形式的临床特征的详细信息尚未被描述。本研究的目的是首次详细研究接种BNT162b2 mRNA COVID-19疫苗后出现的头痛的临床特征。在一项多中心观察性队列研究中，使用标准化在线问卷记录临床特征和相应变量的数据。该问卷分发给德国和阿拉伯联合酋长国的12000家老年养老院以及三级大学医院。本研究的主要结果是接种疫苗后头痛的临床特征。还分析了合并症、药物治疗情况和社会人口统计学变量。共有2349名参与者报告在接种BNT162b2 mRNA COVID-19疫苗后出现头痛。头痛平均在接种后18.0±27.0小时出现，平均持续时间为14.2±21.3小时。只有9.7%的受影响者也报告有先前接种疫苗引起的头痛。66.6%的参与者头痛为单次发作。73.1%的参与者表明头痛为双侧性。最常出现在前额（38.0%）和太阳穴（32.1%）。49.2%的参与者表明疼痛性质为压痛，40.7%报告为钝痛。疼痛强度最常为中度（46.2%）、重度（32.1%）或非常重度（8.2%）。最常见的伴随症状是疲劳（38.8%）、疲惫（25.7%）和肌肉疼痛（23.4%）。COVID-19疫苗接种后的头痛表现出广泛的症状群。伴随症状的组合以及头痛的时间和空间特征界定了一种独特的头痛表型。
